ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc. (ALXO) Revenue
Annual & quarterly revenue history · segment & region breakdown
ALXO · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsALX Oncology Holdings Inc. trailing twelve-month (TTM) revenue is $0.00B, an increase of 0.00% year-over-year from — in FY.
Revenue trend
– · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income ALX Oncology Holdings Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
ALX Oncology Holdings Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from ALX Oncology Holdings Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
ALXO revenue · 4 questionsALXO's trailing twelve-month (TTM) revenue is $0.00B. That is an increase of 0.00% year-over-year from — in FY.
▸ Source: FMP · ALX Oncology Holdings Inc. SEC filings · GAAP · ALX Oncology Holdings Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026